Asker Healthcare Group (OM:ASKER) Earnings Surge Tests Premium P/E And Margin Concerns

Asker Healthcare Group (OM:ASKER) FY 2025 Results Snapshot Asker Healthcare Group (OM:ASKER) has wrapped up FY 2025 with fourth quarter revenue of SEK4.7 billion and basic EPS of 0.34 SEK, setting the tone for how investors assess the full year. Over recent periods, the company has seen quarterly revenue move from SEK4.3 billion and EPS of 0.24 SEK in Q4 2024 to SEK4.7 billion and EPS of 0.34 SEK in Q4 2025. Trailing twelve month EPS came in at 1.25 SEK on revenue of SEK16.8 billion, giving investors a clearer read on how margins are bedding in across the year. See our full analysis for Asker Healthcare Group.With the latest numbers on the table, the next step is to see how this earnings profile lines up against the main narratives around Asker Healthcare Group, and where those stories might need updating. Curious how numbers become stories that shape markets? Explore Community Narratives OM:ASKER Earnings & Revenue History as at Feb 2026 2.9% Net Margin On SEK16.8b TTM Sales Over the last twelve months, Asker generated SEK16.8b in revenue with SEK492 million in net income, which works out to a 2.9% net margin compared with 2.4% a year earlier. What stands out for a bullish view is that earnings growth of 36.7% over the past year sits alongside this 2.9% margin, while the five year earnings growth rate is 3% per year. This means recent profitability trends are stronger than the longer term average even if margins remain relatively thin. 36.7% Earnings Growth Vs 3% Five Year Pace Earnings have grown 36.7% over the last year compared with a 3% per year rate over the past five years, and trailing twelve month EPS is 1.25 SEK. This gives you a sense of how recent performance differs from the longer run. Supporters of a bullish angle often point to this faster recent earnings growth, and here the data gives mixed signals: On one hand, net income on a trailing basis is SEK492 million against SEK360 million a year earlier, which lines up with the idea that profit growth has picked up recently. On the other hand, quarterly net income in FY 2025 ranges between SEK60 million and SEK142 million, so the stronger year still rests on relatively modest absolute profit levels and a margin of 2.9%. Curious how this mix of faster recent earnings growth and thin margins feeds into the bigger story investors are debating around Asker Healthcare Group? 📊 Read the full Asker Healthcare Group Consensus Narrative. P/E Of 50.8x And DCF Fair Value At SEK56.62 Asker trades on a 50.8x P/E compared with peers at 34.7x and the wider European healthcare sector at 19x, while the share price of SEK65.26 sits above a DCF fair value of SEK56.62 and below an analyst price target reference of SEK98.40. Investors who are cautious focus on this gap between valuation and fundamentals, and the numbers underline why: The current multiple is well above both peers and the broader industry even though the trailing net margin is 2.9% and revenue growth is 7.9% per year, which are described as solid but not extreme figures. The company also carries a high level of debt according to the risk summary, so the combination of a premium P/E and a share price above DCF fair value means a lot is already priced in if growth or margins were to soften. Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Asker Healthcare Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. Explore Alternatives Asker Healthcare Group combines thin 2.9% net margins and a high 50.8x P/E with meaningful debt, so a lot of expectation is already priced in. If this leaves you wanting a stronger balance of quality and price, take a look at 224 high quality undervalued stocks, where you can quickly spot candidates that look more reasonably priced today. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free